85 related articles for article (PubMed ID: 10066346)
21. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance.
Hoffmann TK; Dworacki G; Tsukihiro T; Meidenbauer N; Gooding W; Johnson JT; Whiteside TL
Clin Cancer Res; 2002 Aug; 8(8):2553-62. PubMed ID: 12171883
[TBL] [Abstract][Full Text] [Related]
22. Expression of Fas (APO-1/CD95) and Fas ligand (FasL) in human neuroblastoma.
Gross N; Balmas K; Beretta Brognara C; Tschopp J
Med Pediatr Oncol; 2001 Jan; 36(1):111-4. PubMed ID: 11464860
[TBL] [Abstract][Full Text] [Related]
23. ROS-mediated p38alpha MAPK activation and ERK inactivation responsible for upregulation of Fas and FasL and autocrine Fas-mediated cell death in Taiwan cobra phospholipase A(2)-treated U937 cells.
Liu WH; Cheng YC; Chang LS
J Cell Physiol; 2009 Jun; 219(3):642-51. PubMed ID: 19180563
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer.
Shibakita M; Tachibana M; Dhar DK; Kotoh T; Kinugasa S; Kubota H; Masunaga R; Nagasue N
Clin Cancer Res; 1999 Sep; 5(9):2464-9. PubMed ID: 10499620
[TBL] [Abstract][Full Text] [Related]
25. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
[TBL] [Abstract][Full Text] [Related]
26. Immune privilege or inflammation? The paradoxical effects of Fas ligand.
O'Connell J
Arch Immunol Ther Exp (Warsz); 2000; 48(2):73-9. PubMed ID: 10807046
[TBL] [Abstract][Full Text] [Related]
27. Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas.
Shukuwa T; Katayama I; Koji T
Mod Pathol; 2002 Apr; 15(4):387-96. PubMed ID: 11950912
[TBL] [Abstract][Full Text] [Related]
28. Aberrant Fas ligand expression in lymphocytes in patients with Behçet's disease.
Wakisaka S; Takeba Y; Mihara S; Takeno M; Yamamoto S; Sakane T; Suzuki N
Int Arch Allergy Immunol; 2002 Oct; 129(2):175-80. PubMed ID: 12403936
[TBL] [Abstract][Full Text] [Related]
29. [The expression of Fas, FasL and Bcl-2 on RMA cells during the process of apoptosis induced by chemotherapeutic drugs].
Zhu HL; Wang YZ; Yu L; Li B; Yao SQ; Lou FD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Feb; 10(1):35-9. PubMed ID: 12513834
[TBL] [Abstract][Full Text] [Related]
30. [Abnormal Fas and Fas ligand expression of lymphocytes in patients with SLE].
Suzuki N; Sakane T
Nihon Rinsho; 1996 Jul; 54(7):1955-9. PubMed ID: 8741694
[TBL] [Abstract][Full Text] [Related]
31. Fas and Fas ligand expression on human peripheral blood leukocytes.
Mincheff M; Loukinov D; Zoubak S; Hammett M; Meryman H
Vox Sang; 1998; 74(2):113-21. PubMed ID: 9501411
[TBL] [Abstract][Full Text] [Related]
32. Identification of Fas-L-expressing apoptotic T lymphocytes in normal human peripheral blood : in vivo suicide.
De Panfilis G; Caruso A; Sansoni P; Pasolini G; Semenza D; Torresani C
Am J Pathol; 2001 Feb; 158(2):387-91. PubMed ID: 11159176
[TBL] [Abstract][Full Text] [Related]
33. Functional expression of Fas and Fas ligand on human colonic intraepithelial T lymphocytes.
Hongo T; Morimoto Y; Iwagaki H; Kobashi K; Yoshii M; Urushihara N; Hizuta A; Tanaka N
J Int Med Res; 2000; 28(3):132-42. PubMed ID: 10983863
[TBL] [Abstract][Full Text] [Related]
34. A cysteine protease inhibitor prevents activation-induced T-cell apoptosis and death of peripheral blood cells from human immunodeficiency virus-infected individuals by inhibiting upregulation of Fas ligand.
Yang Y; Liu ZH; Ware CF; Ashwell JD
Blood; 1997 Jan; 89(2):550-7. PubMed ID: 9002958
[TBL] [Abstract][Full Text] [Related]
35. Aberrant expression of Fas ligand on anti-DNA autoantibody secreting B lymphocytes in patients with systemic lupus erythematosus: "immune privilege"-like state of the autoreactive B cells.
Nagafuchi H; Wakisaka S; Takeba Y; Takeno M; Sakane T; Suzuki N
Clin Exp Rheumatol; 2002; 20(5):625-31. PubMed ID: 12412192
[TBL] [Abstract][Full Text] [Related]
36. Fas and FasL expression in leukocytes from chronic granulomatous disease patients.
Montes-Berrueta D; Ramírez L; Salmen S; Berrueta L
Invest Clin; 2012 Jun; 53(2):157-67. PubMed ID: 22978048
[TBL] [Abstract][Full Text] [Related]
37. Fas-Fas ligand system in the peripheral blood of patients with renal diseases.
Sato M; Konuma T; Yanagisawa N; Haizuka H; Asakura H; Nakashima Y
Nephron; 2000 Jun; 85(2):107-13. PubMed ID: 10867515
[TBL] [Abstract][Full Text] [Related]
38. Up-regulation of Fas ligand (FasL) mRNA expression in peripheral blood mononuclear cells (PBMC) after major surgery.
Sugimoto M; Shimaoka M; Hosotsubo K; Tanigami H; Taenaka N; Kiyono H; Yoshiya I
Clin Exp Immunol; 1998 Apr; 112(1):120-5. PubMed ID: 9566799
[TBL] [Abstract][Full Text] [Related]
39. Fas and Fas ligand expression in maternal blood and in umbilical cord blood in preeclampsia.
Kuntz TB; Christensen RD; Stegner J; Duff P; Koenig JM
Pediatr Res; 2001 Dec; 50(6):743-9. PubMed ID: 11726734
[TBL] [Abstract][Full Text] [Related]
40. Regulated and endothelial cell-specific expression of Fas ligand: an in vitro model for a strategy aiming at inhibiting xenograft rejection.
Tran TH; Grey S; Anrather J; Steinhäuslin F; Bach FH; Winkler H
Transplantation; 1998 Nov; 66(9):1126-31. PubMed ID: 9825805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
